Cannabis in Switzerland — The Complete 2026 Market Guide

The Market in 2026 — Figures You Should Know

Estimated Swiss CBD market (retail revenue): mid-three-digit million CHF range per year. The share of legal distribution channels has grown significantly, though the classic black market for THC remains dominant for illicit quantities.

Consumption side: Studies show very widespread use — both CBD (wellness, sleep, stress) and THC (especially ages 18–34) are far from marginal phenomena in Switzerland. Detailed figures: /de/blog/cbd-thc-konsum-schweiz-zahlen.

Market split: A growing legal CBD market (from kiosks to pharmacies), a medical THC market (pharmacies plus telemedicine), cantonal pilot projects, and a parallel illicit THC market. It is precisely within this split that the member model positions itself as a legal, fair, and transparent alternative.

Legal Framework — What is Allowed in Switzerland in 2026

CBD and hemp products with less than 1% total THC: Legal to sell, possess, and consume; sales restricted to 18+; tobacco tax applies to smokable products. This is the most liberal framework in Europe.

Medical THC: Prescribable without FOPH (BAG) exceptional permits since August 1, 2022. Available from pharmacies with a standard prescription.

Cannabis pilot projects: Cantonal study projects in Basel-Stadt, Zurich, Bern, Lausanne, and other cities are testing the regulated sale of THC to adult volunteers.

What remains illegal: THC flowers with over 1% THC outside of medical prescriptions and pilot projects, synthetic cannabinoids (HHC banned since 2024), sales to minors, and street dealing.

Full in-depth guide: /de/cannabis-gesetzgebung.

Prices in 2026 — Shop, Pharmacy, and Member Model

Swiss CBD indoor flowers: CHF 5–8/g in shops, CHF 3–4/g from online discounters, and CHF 1–2/g directly from producers via the member model.

Swiss CBD outdoor: CHF 3–5/g in shops, CHF 1–1.50/g via the member model.

CBD oil 10 ml 10%: CHF 30–50 in shops, significantly cheaper via the member model.

Medical THC flowers in pharmacies: CHF 10–15/g; full-spectrum THC oil extract costs around CHF 1.50–3 per daily dose.

Cannabis consultation (telemedicine market): CHF 190 for an initial consultation; member price is CHF 50.

Full price overview: /de/cannabis-preise-schweiz.

Swiss Cultivation — Indoor, Outdoor, and Key Regions

Swiss indoor production is at the top European level in terms of quality and price: controlled climate, dense trichome coverage, and strain-specific terpene profiles. Electricity costs are a major driver — many producers use solar or hydropower to improve margins and carbon footprints.

Swiss outdoor cultivation (mainly in Ticino and southern Valais) delivers cheaper products with a less intense terpene profile. Both cultivation methods have their place in the market; indoor dominates the premium segment.

Main regions in 2026: Valais (sunny tradition, several established indoor facilities), Ticino (mix of outdoor and indoor), Aargau and Central Switzerland (young indoor growers with a solar focus), Bernese region and Romandie (scattered).

Cannabis Pilot Projects — Where Switzerland Breaks New Ground

Cantonal pilot projects for regulated THC sales have been running since 2023: Basel-Stadt ("Weed Care") started, followed by Zurich, Bern, and Lausanne. Participants are adult consumers residing in the respective canton; sales take place in specialized points or pharmacies, featuring quality control and scientific monitoring.

The pilot projects are politically and scientifically crucial: they provide data on the effects of regulation on the black market, youth protection, and consumption behavior. They form the basis for a potential nationwide revision of the Narcotics Act (BetmG).

More details: /de/blog/cannabis-pilotprojekte-schweiz.

Pharmacies — Their Role in the Swiss Cannabis Market

Since the 2022 reform, pharmacies have been the central distribution point for medical THC. Dispensed on a standard prescription, with documented batches and quality-assured processing. In terms of pricing, they represent the most expensive segment (CHF 10–15/g for THC flowers) — the surcharge covers regulatory overhead, consultations, and pharmacy margins.

For many patients, the pharmacy is the natural point of access. Those undergoing long-term treatment who need to watch costs combine pharmacies (for specialized THC formulations) with the member model (for CBD and potentially future club-based THC at wholesale prices).

The Member Model — How Swiss Consumers Save Money

The Cannabis Social Club model originated in Spain and has been adapted to the Swiss legal framework: members pay an annual fee in exchange for access to curated Swiss producers at wholesale prices, collectively negotiated consultations, and group orders.

Concrete figures: Indoor CBD for CHF 1–2/g (instead of CHF 5–8/g in shops), CBD oil correspondingly cheaper, and consultations for CHF 50 instead of CHF 190. As soon as Swiss law permits THC flowers for club members — which the pilot projects and the BetmG revision make likely — we plan to offer THC flowers for CHF 3–4/g (compared to CHF 10–15/g in pharmacies).

More: /de/konzept, /de/blog/cbd-grosshandel-schweiz, /de/cannabis-rezept-schweiz, /de/beitreten.

Shipping, Packaging, and Age Verification — Swiss Standards

Reputable Swiss providers ship in neutral packaging with tracking via Swiss Post, requiring 18+ age verification both at purchase and delivery. There is no indication of the contents on the outer packaging, and batches are fully traceable.

Ordering from EU countries into Switzerland risks customs and BetmG-related issues — the Swiss 1% THC limit applies only to domestic trade. Swiss consumers are best advised to buy from Swiss providers with a registered office in Switzerland.

CBD vs. Medical Cannabis — The Choice in Swiss Practice

For most Swiss consumers, CBD is the right entry point: legal, immediately available, no prescription required, and highly effective for stress, sleep, wellness, and mild ailments.

Medical THC is the answer for more severe chronic indications (MS spasticity, chronic neuropathic pain, palliative care, chemo-induced nausea). This route requires a prescription, a pharmacy, and usually higher monthly costs.

Details: /de/cbd-vs-medizinisches-cannabis, /de/cannabis-medizin.

Consumption Data — Who Uses Cannabis in Switzerland

Surveys show that cannabis consumption in Switzerland is widespread across all ages and regions, with a concentration in the 18–34 age bracket. CBD consumption is growing rapidly and reaching older age groups — many start using CBD for sleep, stress, or pain relief.

More important than raw numbers is the pattern: many consumers combine legal CBD in their daily lives with occasional THC (medical or pilot project) for specific needs. This pattern will shape the Swiss market landscape for years to come.

Detailed figures: /de/blog/cbd-thc-konsum-schweiz-zahlen.

Outlook — What Will Change in the Next 24 Months

Pilot projects will expand to cover more cantons; the results will feed into the BetmG revision. A partially regulated THC supply for adult Swiss consumers — via clubs, pharmacies, or pilot structures — is likely in the medium term.

In the CBD market: A further shift away from kiosk CBD toward curated Swiss indoor brands; wholesale models like the member model will become clearly dominant economically for regular consumers.

Medically: More family doctors prescribing cannabis, better coverage by supplementary health insurance, and clearer clinical guidelines.

FAQ